Search results for "demyelinating"

showing 10 items of 60 documents

Remyelinating strategies in multiple sclerosis.

2014

Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disorder of the CNS characterized by infiltration of immune cells and progressive damage to myelin sheaths and neurons. In recent years, the importance of the neuronal compartment in the early pathology of multiple sclerosis has become increasingly clear. Direct axonal damage within the early stages of inflammation as well as neuronal injury as a result of chronic demyelination are essential factors for the development of long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has significant implications for treatment, with remyelination of denuded axons to protect neurons from dam…

Multiple SclerosisInflammationBiologyNeuroprotectionImmune systemmedicineHumansPharmacology (medical)RemyelinationDemyelinating DisorderMyelin SheathNeuronsGeneral NeuroscienceMultiple sclerosisNeurodegenerationmedicine.diseaseAxonsPathology of multiple sclerosisOligodendrogliamedicine.anatomical_structurenervous systemImmunologyNeurology (clinical)medicine.symptomNeuroscienceImmunosuppressive AgentsDemyelinating DiseasesExpert review of neurotherapeutics
researchProduct

Demyelination patterns in a mathematical model of multiple sclerosis.

2016

In this paper we derive a reaction-diffusion-chemotaxis model for the dynamics of multiple sclerosis. We focus on the early inflammatory phase of the disease characterized by activated local microglia, with the recruitment of a systemically activated immune response, and by oligodendrocyte apoptosis. The model consists of three equations describing the evolution of macrophages, cytokine and apoptotic oligodendrocytes. The main driving mechanism is the chemotactic motion of macrophages in response to a chemical gradient provided by the cytokines. Our model generalizes the system proposed by Calvez and Khonsari (Math Comput Model 47(7–8):726–742, 2008) and Khonsari and Calvez (PLos ONE 2(1):e…

Multiple Sclerosismedicine.medical_treatmentInflammationApoptosisBiology01 natural sciencesModels BiologicalConcentric ring03 medical and health sciences0302 clinical medicineTuring instabilitymedicineHumansMultiple sclerosi0101 mathematicsSettore MAT/07 - Fisica MatematicaInflammationMicrogliaOligodendrocyte apoptosisPatternMultiple sclerosisTuring instabilityApplied MathematicsChemotaxismedicine.diseaseAgricultural and Biological Sciences (miscellaneous)Magnetic Resonance Imaging010101 applied mathematicsChemotaxis PDE modelCytokinemedicine.anatomical_structureModeling and SimulationImmunologymedicine.symptomNeuroscience030217 neurology & neurosurgeryDemyelinating DiseasesJournal of mathematical biology
researchProduct

Neuronavigation-guided biopsy for differential diagnosis of pseudotumoral demyelinating brain lesions

2014

Abstract Marburg's disease (MD) is an extremely rare and aggressive form of multiple sclerosis (MS). In some cases, MD presents with tumefactive demyelinating lesions with a “tumor-like” appearance in MRI images, for which it may be difficult to achieve a form of differential diagnosis between definitive tumors or abscesses. Here we report a case of MD histopathologically confirmed after neuronavigationguided biopsy. Postoperative course was uneventful and following discharge, the patient attended outpatient follow-up appointments and received i.v. cyclophopsphamide, achieving progressive clinical remission. A nine-month follow-up brain MRI scan with gadolinium showed no signs of progressin…

Neuronavigation-guided biopsymedicine.medical_specialtyStereotactic biopsyNeuronavigationlcsh:SurgeryBrain damageDiseaselcsh:RC346-429BiopsyPseudotumoral lesionsmedicineDemyelinating diseaseMarburg's disease (MD); Pseudotumoral lesions; Neuronavigation-guided biopsylcsh:Neurology. Diseases of the nervous systemmedicine.diagnostic_testbusiness.industrySettore MED/27 - NeurochirurgiaMultiple sclerosislcsh:RD1-811medicine.diseaseSurgeryPseudotumoral lesionMarburg's disease (MD)SurgerySettore MED/26 - NeurologiaNeurology (clinical)Differential diagnosismedicine.symptombusinessInterdisciplinary Neurosurgery
researchProduct

Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

2013

Importance Although multiple sclerosis (MS) has long been considered the prototype for an inflammatory, demyelinating disease of the central nervous system, modern histopathology and imaging techniques show that significant damage to neuronal structures already start occurring in the earliest stages of the disease. As the disease progresses, the extent of neuronal pathology accumulates. Therapeutic progress in terms of the prevention of increased disability has only just begun. Objective To review possible diagnostic improvements of neuronal compartment pathology as well as direct therapeutic interventions based on reports from the last decade and outline clinical results from studies and p…

NeuronsMultiple Sclerosisbusiness.industryMultiple sclerosisCentral nervous systemAnti-Inflammatory AgentsDiseasemedicine.diseaseNeuroprotectionClinical trialmedicine.anatomical_structureNeuronal damageNerve DegenerationDemyelinating diseasemedicineDisease ProgressionHumansIdentification (biology)Neurology (clinical)businessNeuroscienceJAMA neurology
researchProduct

Deciphering Multiple Sclerosis Progression

2021

Esclerosi múltiple; Neurodegeneració Esclerosis múltiple; Neurodegeneración Multiple sclerosis; Nneurodegeneration Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, ra…

Oncologymedicine.medical_specialty:Other subheadings::Other subheadings::/physiopathology [Other subheadings]:Otros calificadores::Otros calificadores::/fisiopatología [Otros calificadores]Esclerosi múltiple - Propensió:Genetic Phenomena::Genotype::Genetic Predisposition to Disease [PHENOMENA AND PROCESSES]ReviewDiseaseneurofilamentEsclerosi múltiple - Fisiologia patològicamultiple sclerosislcsh:RC346-429Sistema nerviós - Degeneració03 medical and health sciences0302 clinical medicineDegenerative diseaseInternal medicinemedicineIn patient030212 general & internal medicine:enfermedades del sistema nervioso::enfermedades neurodegenerativas [ENFERMEDADES]lcsh:Neurology. Diseases of the nervous system:fenómenos genéticos::genotipo::predisposición genética a la enfermedad [FENÓMENOS Y PROCESOS]Expanded Disability Status Scalebusiness.industryMultiple sclerosisNeurodegenerationDisease progressionneurodegeneration:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]medicine.diseaseClinical trialprogressive multiple sclerosisNeurology:Nervous System Diseases::Neurodegenerative Diseases [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Neurology (clinical)business030217 neurology & neurosurgeryMRI
researchProduct

The potential of serum neurofilament as biomarker for multiple sclerosis

2021

Abstract Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerativ…

Oncologymedicine.medical_specialtyTreatment responseMultiple SclerosisNeurofilamentFilaments citoplasmàticsDiseaseneurofilamentUpdatesNeurofilament ProteinsInternal medicinemedicineHumans:aminoácidos péptidos y proteínas::proteínas::aminoácidos péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS]Longitudinal StudiesSubclinical disease:Diagnosis::Prognosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Esclerosi múltiple - Imatgeria per ressonància magnètica:diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings]AcademicSubjects/SCI01870business.industrytherapy responseMultiple sclerosis:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]biomarkers:Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores]:Amino Acids Peptides and Proteins::Proteins::Amino Acids Peptides and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS]Prognosismedicine.diseaseEsclerosi múltiple - PrognosiMagnetic Resonance ImagingClinical trialEarly results:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Biomarker (medicine)AcademicSubjects/MED00310Neurology (clinical)businessBrain
researchProduct

Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?

2021

Background and purpose The aim was to identify the clinical and diagnostic investigations that may help to support a diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in patients not fulfilling the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) electrodiagnostic criteria. Methods The data from patients with a clinical diagnosis of CIDP included in a national database were retrospectively reviewed. Results In all, 535 patients with a diagnosis of CIDP were included. This diagnosis fulfilled the EFNS/PNS criteria in 468 patients (87.2%) (definite in 430, probable in 33, possible in three, while two had chronic immune sensory p…

Pediatricsmedicine.medical_specialtyResponse to therapyDatabases FactualNeural ConductionSettore MED/2603 medical and health sciences0302 clinical medicinePeripheral nerveRetrospective StudieMedicineHumansMedical historyIn patient030212 general & internal medicinePeripheral NervesRetrospective Studieschronic inflammatory demyelinating polyradiculoneuropathybusiness.industryPolyradiculoneuropathyPolyradiculopathymedicine.diseaseelectrophysiologySettore MED/26 - NEUROLOGIANeurologyPolyradiculoneuropathy Chronic Inflammatory DemyelinatingClinical diagnosisPeripheral Nervediagnostic criteriaNational databaseNeurology (clinical)chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; electrophysiologybusiness030217 neurology & neurosurgeryHuman
researchProduct

Guillain-Barré Syndrome

2022

Background: Guillain–Barré syndrome is a rare disorder in which our body’s immune system attacks nerves determining weakness and tingling of extremities as first symptoms. It can also be associated to respiratory failure and require mechanical ventilation during hospitalization (up to 30% of patients). Nowadays patient’s hyper-reactive immune responses benefits from immunotherapies such as intravenous immunoglobulin (IVIg), therapeutic plasma exchange (TPE) and new biological drugs. Case Report: We report our experience with the case of a 64-year-old woman who presented a symmetric progressive flaccid paralysis after a week of mild cold symptoms. The respiratory and neurological symptoms wo…

Plasma exchangeAcute inflammatory demyelinating polyneuropathyGeneral MedicineGuillain-Barré syndromeIntravenous immunoglobulinAnnals of Case Reports
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct

Neuroinflammation by cytotoxic T-lymphocytes impairs retrograde axonal transport in an oligodendrocyte mutant mouse.

2012

Mice overexpressing proteolipid protein (PLP) develop a leukodystrophy-like disease involving cytotoxic, CD8+ T-lymphocytes. Here we show that these cytotoxic T-lymphocytes perturb retrograde axonal transport. Using fluorogold stereotactically injected into the colliculus superior, we found that PLP overexpression in oligodendrocytes led to significantly reduced retrograde axonal transport in retina ganglion cell axons. We also observed an accumulation of mitochondria in the juxtaparanodal axonal swellings, indicative for a disturbed axonal transport. PLP overexpression in the absence of T-lymphocytes rescued retrograde axonal transport defects and abolished axonal swellings. Bone marrow tr…

Retinal Ganglion CellsProteolipid protein 1MouseCD8-Positive T-LymphocytesGranzymesMyelinMiceBone Marrow TransplantationNeuronsddc:616MultidisciplinarybiologyQRNeurodegenerative DiseasesAnimal ModelsCell biologyOligodendrogliamedicine.anatomical_structureNeurologyMedicineResearch ArticleHeterozygoteMultiple SclerosisProteolipidsScienceImmunologyMice Transgenicchemical and pharmacologic phenomenaAutoimmune DiseasesModel OrganismsmedicineAnimalsBiologyNeuroinflammationInflammationImmunityDemyelinating DisordersOligodendrocyteAxonsGranzyme BPerforinGranzymenervous systemImmune SystemImmunologyMutationAxoplasmic transportbiology.proteinClinical ImmunologyMolecular NeuroscienceT-Lymphocytes CytotoxicNeurosciencePLoS ONE
researchProduct